$CERU moving in an orderly fashion above the up
Post# of 99241
(Total Views: 110)
Posted On: 03/16/2017 3:56:57 PM
$CERU moving in an orderly
fashion above the upper bollie.
$3.08
Website
10-Q 11/3/16
Ultra low float
Shares Outstanding 27.44M
Float 18.03M
% Held by Insiders 33.41%
% Held by Institutions 47.20%
Shares Short 3 1.52M
Short Ratio 0.44
Short % of Float 11.60%
Shares Short (prior month) 924.47k
No particular news except Seeking Alpha
has been following it publicly on positive moves.
Premarket Gainers as of 9:10 am
SA News•Today, 9:20 AM•1 Comment
After Hours Gainers / Losers
SA News•Yesterday, 5:35 PM•1 Comment
Midday Gainers / Losers
SA News•Yesterday, 12:43 PM
Healthcare- Top 5 Gainers / Losers as of 12:15 PM
SA News•Yesterday, 12:15 PM
Cerulean up 44% in early trading
SA News•Yesterday, 10:46 AM•12 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Yesterday, 9:15 AM
Premarket Gainers / Losers as of 9:10 am
SA News•Tue, Mar. 14
Midday Gainers / Losers
SA News•Mon, Mar. 13•13 Comments
Healthcare - Top 5 Gainers / Losers as of 12:10 PM
SA News•Mon, Mar. 13•2 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Mon, Mar. 13•3 Comments
Healthcare - Top 5 Gainers / Losers as of 11:00 am
SA News•Thu, Feb. 9•2 Comments
Healthcare - Top 5 Gainers / Losers as of 11:00 am
SA News•Tue, Feb. 7•8 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Mon, Feb. 6•4 Comments
Cerulean Pharma receives deficiency notice from Nasdaq
SA News•Nov. 18, 2016•6 Comments
Cerulean Pharma Inc. SEC Filing - Current report (8-K) November 18, 2016
SEC Filings•Nov. 18, 2016
Other News
3 Reasons Why Cerulean Pharma (CERU) is a Great Momentum Stock
at Zacks.com (Jan 9, 2017)
Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
at TheStreet (Oct 26, 2016)
First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
at TheStreet (Oct 25, 2016)
Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration
at Benzinga (Oct 19, 2016)
Cerulean Stock Shoots Higher On News Of Novartis Collaboration
at Benzinga (Oct 19, 2016)
Cerulean Announces Technology Platform Collaboration
at TheStreet (Oct 19, 2016)
Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
at TheStreet (Oct 6, 2016)
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
at Benzinga (Aug 30, 2016)
Cerulean Announces Reduction In Force
at TheStreet (Aug 18, 2016)
Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
at TheStreet (Aug 18, 2016)
< >
Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The companys lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company has a strategic collaboration with Novartis to develop nanoparticle-drug conjugates for various cancer tumor targets. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.
fashion above the upper bollie.
$3.08
Website
10-Q 11/3/16
Ultra low float
Shares Outstanding 27.44M
Float 18.03M
% Held by Insiders 33.41%
% Held by Institutions 47.20%
Shares Short 3 1.52M
Short Ratio 0.44
Short % of Float 11.60%
Shares Short (prior month) 924.47k
No particular news except Seeking Alpha
has been following it publicly on positive moves.
Premarket Gainers as of 9:10 am
SA News•Today, 9:20 AM•1 Comment
After Hours Gainers / Losers
SA News•Yesterday, 5:35 PM•1 Comment
Midday Gainers / Losers
SA News•Yesterday, 12:43 PM
Healthcare- Top 5 Gainers / Losers as of 12:15 PM
SA News•Yesterday, 12:15 PM
Cerulean up 44% in early trading
SA News•Yesterday, 10:46 AM•12 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Yesterday, 9:15 AM
Premarket Gainers / Losers as of 9:10 am
SA News•Tue, Mar. 14
Midday Gainers / Losers
SA News•Mon, Mar. 13•13 Comments
Healthcare - Top 5 Gainers / Losers as of 12:10 PM
SA News•Mon, Mar. 13•2 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Mon, Mar. 13•3 Comments
Healthcare - Top 5 Gainers / Losers as of 11:00 am
SA News•Thu, Feb. 9•2 Comments
Healthcare - Top 5 Gainers / Losers as of 11:00 am
SA News•Tue, Feb. 7•8 Comments
Premarket Gainers / Losers as of 9:10 am
SA News•Mon, Feb. 6•4 Comments
Cerulean Pharma receives deficiency notice from Nasdaq
SA News•Nov. 18, 2016•6 Comments
Cerulean Pharma Inc. SEC Filing - Current report (8-K) November 18, 2016
SEC Filings•Nov. 18, 2016
Other News
3 Reasons Why Cerulean Pharma (CERU) is a Great Momentum Stock
at Zacks.com (Jan 9, 2017)
Cerulean Announces Promotion Of Scott Eliasof, PhD To Senior Vice President And Chief Scientific Officer
at TheStreet (Oct 26, 2016)
First Week of June 2017 Options Trading For Cerulean Pharma (CERU)
at TheStreet (Oct 25, 2016)
Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration
at Benzinga (Oct 19, 2016)
Cerulean Stock Shoots Higher On News Of Novartis Collaboration
at Benzinga (Oct 19, 2016)
Cerulean Announces Technology Platform Collaboration
at TheStreet (Oct 19, 2016)
Cerulean Announces Data Presentations At The 2016 European Society For Medical Oncology Annual Meeting
at TheStreet (Oct 6, 2016)
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
at Benzinga (Aug 30, 2016)
Cerulean Announces Reduction In Force
at TheStreet (Aug 18, 2016)
Cerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure
at TheStreet (Aug 18, 2016)
< >
Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The companys lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company has a strategic collaboration with Novartis to develop nanoparticle-drug conjugates for various cancer tumor targets. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.
(0)
(0)